Pacific Biosciences of California, Inc.
Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +40.8%. Concerns: 50-day MA is falling (-10.05% over 10 days); RSI 80 — overbought, elevated pullback risk; 3-month momentum negative (-23.5%). Currently 38.1% off its 52-week high. Score: +1/7.
PACB is in a confirmed uptrend, trading above both its 50-day ($1.51) and 200-day ($1.68) moving averages. With an RSI of 80.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +40.8% compares to +35.1% for SPY (beat the market by 5.7%). The current 38.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.